Fibrin Composition with Arg-Gly-Asp Protein Blocks for Bone Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing methods for preparing platelet-rich fibrin (PRF) rely on glass blood collection tubes that activate coagulation factor XII, leading to environmental concerns and biosafety issues, while plastic tubes lack re-administration safety and efficiency in PRF preparation.
Innovation Solution
A fibrin composition is developed using a plastic blood collection tube with blocks containing a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, which promotes bone regeneration by mimicking the coagulation process without activating coagulation factors, thereby substituting traditional glass tubes and enhancing safety and efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glass blood collection tubes are used to prepare PRF, then coagulation factor XII is activated and fibrin clots are formed, but environmental concerns arise and manufacturing has been discontinued
Solution Approach 1:
The patent introduces a plastic blood collection tube with a special film as an intermediary substitute for glass tubes. The film contains silica particles that mediate the coagulation activation process, allowing factor XII activation without requiring glass material. This resolves the contradiction by maintaining the functional reliability of coagulation activation while eliminating the manufacturing discontinuation issue of glass tubes.
Solution Approach 2:
The patent changes the material parameter of the blood collection tube from glass to plastic with a specialized film coating. This parameter change maintains the essential function of coagulation activation through silica-containing film while making the tube manufacturable and environmentally acceptable, thus resolving both the reliability and ease of manufacture aspects.
2Ease of manufacture
If plastic blood collection tubes are used for PRF preparation, then manufacturing continuity is maintained, but coagulation activation and re-administration safety are compromised
Solution Approach 1:
The patent creates a composite structure by combining plastic material with a silica-containing film coating. The plastic provides manufacturability and safety, while the silica film restores the coagulation activation function. This composite approach resolves the contradiction by integrating the advantages of both materials.
Solution Approach 2:
The silica-containing film acts as an intermediary layer between the plastic tube and blood, enabling coagulation activation without requiring the blood to contact glass directly. This mediator approach maintains manufacturing continuity while restoring coagulation reliability.
3Quantity of substance
If traditional PRF preparation methods are used, then platelet-rich fibrin is obtained, but biosafety concerns arise due to glass tube discontinuation
Solution Approach 1:
The patent adopts disposable plastic blood collection tubes with silica film as a safe alternative to glass tubes. These disposable tubes eliminate biosafety risks associated with glass tube discontinuation while maintaining PRF production capability. The plastic material with specialized coating provides a safe, single-use solution that resolves the biosafety concern.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fibrin composition effectively induces bone regeneration by synergizing with platelet-rich fibrin, offering a safer, more cost-effective alternative to traditional glass tubes and improving the consistency of PRF preparation.
Implementation Method 1
a fibrin composition which includes blocks each including a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, fibrin, and platelets
Data Source
AI summary
An object of the present invention is to provide a fibrin composition manufactured by a method as a substitute for a method for manufacturing platelet-rich fibrin (PRF) triggered by the activation of a coagulation factor, a substrate for regenerative medicine using the fibrin composition, a method for manufacturing a fibrin composition, and a kit for being used in the method. According to the present invention, there is provided a fibrin composition including blocks, which each include a protein having repetitive Arg-Gly-Asp sequences derived from human collagen, fibrin, and platelets.